At #DrugDiscoveryOnTarget, our CSO, Dominic Reynolds, will highlight REM-422, our first-in-class mRNA degrader targeting the MYB oncogene, and discuss how our REMaster® platform is enabling new approaches to previously undruggable RNA targets.
#RNATherapeutics #DrugDiscovery
